{"id":2322,"date":"2015-10-16T21:06:12","date_gmt":"2015-10-16T19:06:12","guid":{"rendered":"https:\/\/blog.uchceu.es\/farmacia\/?p=2322"},"modified":"2021-04-27T08:18:53","modified_gmt":"2021-04-27T06:18:53","slug":"ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria","status":"publish","type":"post","link":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/","title":{"rendered":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria."},"content":{"rendered":"<p><a href=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-2324 aligncenter\" src=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis-315x145.jpg\" alt=\"esclerosis\" width=\"569\" height=\"262\" srcset=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis-315x145.jpg 315w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg 650w\" sizes=\"auto, (max-width: 569px) 100vw, 569px\" \/><\/a><\/p>\n<p>La <a href=\"https:\/\/esclerosismultiple.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">esclerosis m\u00faltiple<\/a> (EM) es una enfermedad cr\u00f3nica autoinmune que puede resultar incapacitante ya que afecta al sistema nervioso central. La EM se produce cuando las c\u00e9lulas del sistema inmunitario reaccionan de forma err\u00f3nea y comienzan a atacar las vainas de mielina. Esto se manifiesta en el enfermo, en forma de fatiga, debilidad, problemas motores&#8230;<\/p>\n<p>En los \u00faltimos 15 a\u00f1os, tanto la prevalencia como la incidencia de la EM se ha duplicado y a d\u00eda de hoy, ya afecta a <span style=\"color: #ff9900\"><em><strong>2,3 millones de personas en el mundo, 50.000 personas en Espa\u00f1a<\/strong><\/em><\/span>. El 15% de estos pacientes padecen EM primaria progresiva, que no ten\u00edan alternativa terap\u00e9utica y su deterioro neurol\u00f3gico es imparable. Este tipo de EM tiene un inicio lento con empeoramiento constante de los s\u00edntomas hasta que incapacita al paciente.<\/p>\n<blockquote><p><strong><span style=\"color: #ff0000\">\u00abAntes, los diagnostic\u00e1bamos muy bien pero no pod\u00edamos ofrecerles ning\u00fan f\u00e1rmaco para alterar la evoluci\u00f3n de la enfermedad, s\u00f3lo tratarlos de forma asintom\u00e1tica con neurorrehabilitaci\u00f3n<\/span><\/strong><span style=\"color: #ff0000\">\u00ab<\/span> <span style=\"color: #339966\">Montalb\u00e1n, m\u00e9dico del servicio de neurolog\u00eda de Vall d\u00b4Hebron.<\/span><\/p><\/blockquote>\n<p>El equipo del Centro de Esclerosis M\u00faltiple de Vall d\u00b4Hebron junto a la farmac\u00e9utica Roche, han llevado a cabo una investigaci\u00f3n que prueba que el f\u00e1rmaco Ocrelizumab (anticuerpo monoclonal humanizado para actuar sobre los linfocitos B CD20 positivos) reduce \u00a0de 12 a 24 semanas la progresi\u00f3n de la EM primaria progresiva.<\/p>\n<p>Este f\u00e1rmaco se ha estudiado en el <strong>ensayo Oratorio<\/strong>, de fase III internacional multic\u00e9ntrico, aleatorizado y doble ciego, en el que se evaluaba la eficacia y seguridad de <strong>ocrelizumab<\/strong> \u00a0f<strong>rente a placebo<\/strong> e<strong>n 732 pacientes con EMPP.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>M\u00e1s informaci\u00f3n: estudio sobre ocrelizumab.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La esclerosis m\u00faltiple (EM) es una enfermedad cr\u00f3nica autoinmune que puede resultar incapacitante ya que afecta al sistema nervioso central. La EM se produce cuando las c\u00e9lulas del sistema inmunitario reaccionan de forma err\u00f3nea y comienzan a atacar las vainas de mielina. Esto se manifiesta en el enfermo, en forma de fatiga, debilidad, problemas motores&#8230; [&hellip;]<\/p>\n","protected":false},"author":362,"featured_media":2324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[20,44],"class_list":{"0":"post-2322","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-divulgacion-cientifica","8":"tag-atencion-farmaceutica","9":"tag-innovaciones-terapeuticas"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.\" \/>\n<meta property=\"og:description\" content=\"La esclerosis m\u00faltiple (EM) es una enfermedad cr\u00f3nica autoinmune que puede resultar incapacitante ya que afecta al sistema nervioso central. La EM se produce cuando las c\u00e9lulas del sistema inmunitario reaccionan de forma err\u00f3nea y comienzan a atacar las vainas de mielina. Esto se manifiesta en el enfermo, en forma de fatiga, debilidad, problemas motores&#8230; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Farmacia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FarmaciaUCH\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-16T19:06:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-27T06:18:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Universidad CEU Cardenal Herrera\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Universidad CEU Cardenal Herrera\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\"},\"author\":{\"name\":\"Universidad CEU Cardenal Herrera\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\"},\"headline\":\"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.\",\"datePublished\":\"2015-10-16T19:06:12+00:00\",\"dateModified\":\"2021-04-27T06:18:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\"},\"wordCount\":300,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\",\"keywords\":[\"Atenci\u00f3n Farmac\u00e9utica\",\"innovaciones terap\u00e9uticas\"],\"articleSection\":[\"Divulgaci\u00f3n Cient\u00edfica\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\",\"name\":\"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\",\"datePublished\":\"2015-10-16T19:06:12+00:00\",\"dateModified\":\"2021-04-27T06:18:53+00:00\",\"author\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\"},\"breadcrumb\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\",\"contentUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg\",\"width\":650,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Divulgaci\u00f3n Cient\u00edfica\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/\",\"name\":\"Blog de Farmacia\",\"description\":\"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64\",\"name\":\"Universidad CEU Cardenal Herrera\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g\",\"caption\":\"Universidad CEU Cardenal Herrera\"},\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/author\/sgomez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/","og_locale":"es_ES","og_type":"article","og_title":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.","og_description":"La esclerosis m\u00faltiple (EM) es una enfermedad cr\u00f3nica autoinmune que puede resultar incapacitante ya que afecta al sistema nervioso central. La EM se produce cuando las c\u00e9lulas del sistema inmunitario reaccionan de forma err\u00f3nea y comienzan a atacar las vainas de mielina. Esto se manifiesta en el enfermo, en forma de fatiga, debilidad, problemas motores&#8230; [&hellip;]","og_url":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/","og_site_name":"Blog de Farmacia","article_publisher":"https:\/\/www.facebook.com\/FarmaciaUCH","article_published_time":"2015-10-16T19:06:12+00:00","article_modified_time":"2021-04-27T06:18:53+00:00","og_image":[{"width":650,"height":300,"url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg","type":"image\/jpeg"}],"author":"Universidad CEU Cardenal Herrera","twitter_misc":{"Escrito por":"Universidad CEU Cardenal Herrera","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#article","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/"},"author":{"name":"Universidad CEU Cardenal Herrera","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64"},"headline":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.","datePublished":"2015-10-16T19:06:12+00:00","dateModified":"2021-04-27T06:18:53+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/"},"wordCount":300,"commentCount":0,"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg","keywords":["Atenci\u00f3n Farmac\u00e9utica","innovaciones terap\u00e9uticas"],"articleSection":["Divulgaci\u00f3n Cient\u00edfica"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/","url":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/","name":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria.","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage"},"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg","datePublished":"2015-10-16T19:06:12+00:00","dateModified":"2021-04-27T06:18:53+00:00","author":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64"},"breadcrumb":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#primaryimage","url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg","contentUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/esclerosis.jpg","width":650,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/blog.uchceu.es\/farmacia\/ocrelizumab-farmaco-experimental-que-reduce-la-progresion-de-la-esclerosis-multiple-primaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/blog.uchceu.es\/farmacia\/"},{"@type":"ListItem","position":2,"name":"Divulgaci\u00f3n Cient\u00edfica","item":"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/"},{"@type":"ListItem","position":3,"name":"Ocrelizumab, f\u00e1rmaco experimental que reduce la progresi\u00f3n de la Esclerosis M\u00faltiple primaria."}]},{"@type":"WebSite","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website","url":"https:\/\/blog.uchceu.es\/farmacia\/en\/","name":"Blog de Farmacia","description":"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/af2066106dd55a3190aa183d57d43c64","name":"Universidad CEU Cardenal Herrera","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f89f18ab075211f8a01caec13267c8a5a30f269905bae9be956e705f52e3f5d0?s=96&d=mm&r=g","caption":"Universidad CEU Cardenal Herrera"},"url":"https:\/\/blog.uchceu.es\/farmacia\/author\/sgomez\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/users\/362"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/comments?post=2322"}],"version-history":[{"count":1,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2322\/revisions"}],"predecessor-version":[{"id":6066,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2322\/revisions\/6066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media\/2324"}],"wp:attachment":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media?parent=2322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/categories?post=2322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/tags?post=2322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}